Ambu surges after FDA clearance for 'niche' tool

Ambu A/S

20/09/2023 11:13

** Shares in Ambu  AMBUb.CO  rise 5% after the Danish
medical equipment maker received clearance from the U.S. Food
and Drug Administration (FDA) for its new single-use colonoscope
    ** Carnegie analyst Niels Granholm Leth says that Ambu's
announcement on FDA clearance comes "earlier than the market
expected", explaining the shares uprise  
    ** Sydbank analyst Soren Lontoft Hansen adds that the
company's move to launch its colonoscope constitutes a strategic
pivot towards targeting a niche area within colonoscopy
    ** The company is strategically positioning itself to
address a "very small fraction in a very large market", Hansen
notes
    ** Ambu says it will now apply an initial market test
approach in a few dedicated U.S. centers to evaluate clinical
performance
    ** Share is on track for its best day since May, among best
performers of pan-European 600 index  .STOXX 

 (Reporting by Jesus Calero)
 ((Jesus.calero@thomsonreuters.com))